These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2865111)

  • 21. Ibuprofen and sulindac kinetics in alcoholic liver disease.
    Juhl RP; Van Thiel DH; Dittert LW; Albert KS; Smith RB
    Clin Pharmacol Ther; 1983 Jul; 34(1):104-9. PubMed ID: 6861431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of sulindac with other cyclooxygenase inhibitors on prostaglandin excretion and renal function in normal and chronic bile duct-ligated dogs and swine.
    Zambraski EJ; Chremos AN; Dunn MJ
    J Pharmacol Exp Ther; 1984 Mar; 228(3):560-6. PubMed ID: 6423807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
    Ravis WR; Diskin CJ; Campagna KD; Clark CR; McMillian CL
    J Clin Pharmacol; 1993 Jun; 33(6):527-34. PubMed ID: 8366178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulindac disposition when given once and twice daily.
    Swanson BN; Boppana VK; Vlasses PH; Holmes GI; Monsell K; Ferguson RK
    Clin Pharmacol Ther; 1982 Sep; 32(3):397-403. PubMed ID: 7049504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A kinetic study of sulindac in the elderly.
    Bayley N; Warne RW; Moulds RF; Bury RW
    Aust N Z J Med; 1987 Feb; 17(1):39-42. PubMed ID: 3476045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the biologically active form of sulindac.
    Duggan DE; Hooke KF; Risley EA; Shen TY; Arman CG
    J Pharmacol Exp Ther; 1977 Apr; 201(1):8-13. PubMed ID: 850147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible mechanisms for reduced plasma clearance of diflunisal in rat experimental renal failure.
    Lin JH; Ulm EH; Duggan DE
    J Pharmacol Exp Ther; 1986 Sep; 238(3):978-84. PubMed ID: 3746671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Sulindac.
    Kwan KC; Duggan DE
    Acta Rhumatol Belg; 1977; 1(3-4):168-78. PubMed ID: 756665
    [No Abstract]   [Full Text] [Related]  

  • 29. Renal metabolism of sulindac, a novel nonsteroidal antiinflammatory agent.
    Miller MJ; Bednar MM; McGiff JC
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():487-91. PubMed ID: 6221568
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of sulindac and its metabolites on acute stress-induced gastric ulcers in rats.
    Glavin GB; Sitar DS
    Toxicol Appl Pharmacol; 1986 Apr; 83(2):386-9. PubMed ID: 3961821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The roles of renal catabolism and uremia in modifying the clearance of fibrinogen and its degradative fragments D and E.
    Iio A; Rutherford WE; Wochner RD; Spilberg I; Sherman LA
    J Lab Clin Med; 1976 Jun; 87(6):934-46. PubMed ID: 932524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The disposition of sulindac.
    Duggan DE; Hare LE; Ditzler CA; Lei BW; Kwan KC
    Clin Pharmacol Ther; 1977 Mar; 21(3):326-35. PubMed ID: 300048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose ceftriaxone kinetics in functionally anephric patients.
    Stoeckel K; McNamara PJ; Hoppe-Seyler G; Blumberg A; Keller E
    Clin Pharmacol Ther; 1983 May; 33(5):633-41. PubMed ID: 6301740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual variability in concentrations of urinary sulindac sulfide.
    Brandli DW; Sarkissian E; Ng SC; Paulus HE
    Clin Pharmacol Ther; 1991 Dec; 50(6):650-5. PubMed ID: 1752108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide.
    Leite S; Martins NM; Dorta DJ; Curti C; Uyemura SA; dos Santos AC
    Basic Clin Pharmacol Toxicol; 2006 Oct; 99(4):294-9. PubMed ID: 17040214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative disposition of sulindac and metabolites in five species.
    Duggan DE; Hooke KF; Noll RM; Hucker HB; Van Arman CG
    Biochem Pharmacol; 1978; 27(19):2311-20. PubMed ID: 103551
    [No Abstract]   [Full Text] [Related]  

  • 37. Sulindac sulfide inhibits Ras signaling.
    Herrmann C; Block C; Geisen C; Haas K; Weber C; Winde G; Möröy T; Müller O
    Oncogene; 1998 Oct; 17(14):1769-76. PubMed ID: 9778042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenoxicam pharmacokinetics in rats: a population model.
    Troconiz IF; Lopez-Bustamante LG; Fos D
    J Pharm Sci; 1995 Dec; 84(12):1482-7. PubMed ID: 8748332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane effects of antiinflammatory agents. 1. Interaction of sulindac and its metabolites with phospholipid membrane, a magnetic resonance study.
    Fan SS; Shen TY
    J Med Chem; 1981 Oct; 24(10):1197-202. PubMed ID: 6276543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
    Thompson HJ; Jiang C; Lu J; Mehta RG; Piazza GA; Paranka NS; Pamukcu R; Ahnen DJ
    Cancer Res; 1997 Jan; 57(2):267-71. PubMed ID: 9000566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.